A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rafael Bejar, MD, PhD
Aptose Biosciences Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California Los Angeles
Los Angeles, California, United States
- Pacific Cancer Care
Monterey, California, United States
- Torrance Memorial Physician Network
Redondo Beach, California, United States
- Sharp Clinical Oncology Research
San Diego, California, United States
- Ucsd Moores Cancer Center
San Diego, California, United States
- Ridley-Tree Cancer Center
Santa Barbara, California, United States
- St. Joseph Heritage Heathcare
Santa Rosa, California, United States
- Rocky Mountain Cancer Centers
Aurora, Colorado, United States
- Mayo Clinic Jacksonville
Jacksonville, Florida, United States
- Orlando Health
Orlando, Florida, United States
- Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
- University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
- the Center for Cancer and Blood Disorders A Division of American Oncology Partners of Maryland, Pa
Bethesda, Maryland, United States
- Umass Memorial Medical Center
Worcester, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Scl Health, St. Vincent Frontier Cancer Center
Billings, Montana, United States
- Morristown Medical Center
Morristown, New Jersey, United States
- Manhattan Hematology Oncology
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Prisma Health - Itor
Greenville, South Carolina, United States
- Carolina Blood and Cancer Care Associates
Rock Hill, South Carolina, United States
- Texas Oncology - Austin-Midtown
Austin, Texas, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
- Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, United States
- University of Texas, M.D. Anderson Cancer Center
Houston, Texas, United States
- University of Texas Health Science Center at San Antonio, Mays Cancer Center
San Antonio, Texas, United States
- Texas Oncology - Tyler
Tyler, Texas, United States
- Virginia Oncology Associates
Norfolk, Virginia, United States
- Northwest Cancer Specialists, P.C. - Compass Oncology
Vancouver, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2019
- Primary completion
- 17 May 2024
- Completion
- 17 May 2024
- Last update posted
- 7 Mar 2025
- Registered enrollment
- 36
- Registry id
- NCT03893682
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.